AstraZeneca strikes $1 billion deal for rare-disease drug maker

AstraZeneca on Thursday struck a $1 billion deal to buy a maker of drug for rare diseases, further building out the capabilities it acquired in the 2021 deal for Alexion Pharmaceuticals.

Previous post Lanxess shares slide as German chemicals company forecasts moderate improvement from ‘crisis’ year
Next post Retail traders last week rotated into Apple and Boeing, away from Nvidia